Iron Deficiency In Pulmonary Hypertension

Idiopathic Pulmonary Arterial Hypertension Clinical Trial

Official title:

Intravenous Iron Treatment In Iron Deficient Patients With Idiopathic Pulmonary Arterial Hypertension

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01288651
• Other study ID #: 2010-247
• Status: Recruiting
• Phase: Phase 4
• First received: February 1, 2011
• Last updated: February 1, 2011
• Start date: January 2011
• Est. completion date: January 2013

Study information

• Verified date: January 2011
• Source: VU University Medical Center
• Contact: Gerrina Ruiter, MD
• Phone: +31 20 444 4915
• Email: G.Ruiter[@]vumc.nl
• Is FDA regulated: No
• Health authority: Netherlands: Medical Ethics Review Committee (METC)
• Study type: Interventional

Clinical Trial Summary

Patients with idiopathic pulmonary arterial hypertension (IPAH) and iron deficiency were previously shown to have a decreased six-minute walking distance. Therefore the investigators hypothesized that intravenous iron administration would improve exercise capacity in iron deficient IPAH patients.

30 patients will be recruited for iron infusions. At baseline and after 12 weeks (endpoint)exercise test will be performed.

Description:

Background: Patients with pulmonary arterial hypertension (PAH) develop progressive right heart failure which eventually will lead to death. During progression of the disease the physical performance of the patients deteriorates. Maintaining their exercise capacity is a major goal in PAH treatment. Iron treatment is known to have a positive effect on physical performance in patients with left heart failure and iron deficiency. Whether this is also effective in patients with right heart failure (PAH) and iron deficiency is until now unknown.

Objective: To evaluate the effects of intravenous iron supplementation on exercise capacity in iron deficient IPAH patients.

Study design: Intervention study

Study population: Patients with idiopathic pulmonary arterial hypertension (IPAH) and iron deficiency

Patients receive an iron bolus infusion of 1000 mg iron after baseline measurements.

Main study parameters/endpoints:

Primary endpoint: six minute walking distance (6WMD) Secondary endpoints: cardiopulmonary exercise test, myoglobin concentration in quadriceps muscle, quadriceps muscle fiber strength, serum iron parameters, serum inflammatory parameters, quality of life (QOL), and NYHA functional class.

The patients will be hospitalised two days at the beginning and two days at the end of the study to perform the exercise and strength tests, six minute walking distance and for biopsy of the quadriceps muscle. Also NYHA functional class will be determined and a QOL questionnaire has to be filled in. After the baseline measurements an iron infusion will be given (Ferinject 1000mg).

The investigators hypothesize that iron deficient IPAH patients will benefit from iron treatment with improved exercise capacity reflected in an increased 6MWD.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: January 2013
• Est. primary completion date: December 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Stable idiopathic pulmonary arterial hypertension (stable disease for at least 3 months)

• iron deficiency (serum iron below 10 µmol/l, decreased transferrin saturation (< 15% in females and < 20% in males) and serum ferritin < 100 µg/l) irrespective of the coexistence of anaemia

Exclusion Criteria:

• Current iron therapy (oral or iv)

• Current other study medication for PAH

• History of anaemia or current treatment for anaemia

• Liver function impairment

• Chronic disease other than PAH (rheumatism, asthma, chronic infection)

• Acute infection

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hypertension
• Idiopathic Pulmonary Arterial Hypertension

Intervention

Drug:
• Ferricarboxymaltose
Ferricarboxymaltose (Ferinject®, Vifor Pharma) is used for intravenous iron administration. This iron is administered in high dose iron infusion of 1000 mg iron (equals 20 ml Ferinject) in 250 ml saline in the vein (infusion site)within 2 hours. During infusion, patients will be observed and blood pressure and heart rate are monitored before and after administration. Four weeks after iron administration, iron parameters are measured in the general practitioners setting. When iron parameters are still under normal values, a repeat infusion will be given of 500 mg iron (equals 10 ml Ferinject).

Locations

Country	Name	City	State
Netherlands	VUmc	Amsterdam

Sponsors (2)

Lead Sponsor	Collaborator
VU University Medical Center	Vifor Pharma

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	six-minute walking distance	The primary endpoint is improvement in six-minute walking distance	12 weeks	No
Secondary	Serum iron parameters	Serum iron parameters and inflammatory parameters are measured	0 and 12 weeks	No
Secondary	Exercise capacity	Cardiopulmonary exercise testing is performed to measure maximal exercise capacity and exercise endurance time.	0 and 12 weeks	No
Secondary	Quadriceps muscle function	A biopsy from the quadriceps muscle is taken for histochemical analysis, myoglobin measurements and muscle fiber strength characteristics	0 and 12 weeks	No
Secondary	Cardiac Function	A cardiac MRI is performed to measure cardiac function	0 and 12 weeks	No
Secondary	Quality of life	Quality of life and NYHA functional class is established.	0 and 12 weeks	No